Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Aktis Oncology initiated a Phase 1b clinical trial for AKY-2519, a B7-H3 targeted miniprotein radioconjugate, evaluating it in metastatic castration-resistant prostate cancer (mCRPC) patients including those naïve and experienced with PLUVICTO®. A parallel Phase 1b basket trial is planned for other B7-H3 expressing tumors such as lung and colorecta…